Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn¿s Disease and Ulcerative Colitis Francisco Rodríguez-Moranta; Federico Argüelles-Arias; Joaquín Hinojosa del Val; Marisa Iborra Colomino; M. Dolores Martín-Arranz; Luis Menchén Viso; Fernando Muñoz Núñez; Elena Ricart Gómez; José Germán Sánchez-Hernández; Teresa Valdés-Delgado; Jordi Guardiola Capón; Manuel Barreiro-de Acosta; Míriam Mañosa Ciria; Yamile Zabana Abdo; Ana Gutiérrez Casbas;

Recommendations of the Spanish Working Group on Crohn¿s disease and Ulcerative Colitis (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa ¿ GETECCU) on dysplasia screening in inflammatory bowel disease patients Beatriz Sicilia; Raquel Vicente; Lara Arias; Ana Echarri; Yamile Zabana; Miriam Mañosa; Belén Beltrán; Manuel Barreiro-de Acosta;

COVID-19 and inflammatory bowel disease: Questions arising from patient care and follow-up during the initial phase of the pandemic (February¿April 2020) Ignacio Marín-Jiménez; Yamile Zabana; Iago Rodríguez-Lago; Laura Marín; Manuel Barreiro-de Acosta; María Esteve;